Navigation Links
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Date:11/15/2010

harmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam Kidron, at the Tenth Annual Meeting of the Diabetes Technology Society, in Bethesda, Maryland.

The poster presentation entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," described Oramed's first extended exposure study to its oral insulin product (ORMD-0801), where 21 patients were treated with ORMD-0801, self-administered daily for a period of six weeks. In parallel, a group of eight patients received placebo capsules administered under the same treatment regimen. ORMD-0801 proved safe and tolerable, with no reports of serious adverse events throughout the study. In addition, no cumulative effects of extended ORMD-0801 exposure were noted, and only two mild cases of transient hypoglycemia were reported. Treatment efficacy was evaluated via markers quantified from blood samples drawn at the start and end of the study. Daily administration of oral insulin led to a statistically significant decrease in both insulin and C-reactive protein (CRP) levels, in contrast to their elevation among placebo-treated individuals. Moreover, the percentage of subjects demonstrating clinically relevant reductions in insulin, c-peptide, fasting blood glucose (FBG) and Hb1Ac levels was consistently higher in the ORMD-0801 cohort, when compared to its placebo counterpart. This study addressing, for the first time, potential long-term safety concerns from extended ORMD-0801 administrations, demonstrated safety and no seri
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
2. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
9. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
10. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... 2015 , ... Cuvettes have been used in countless labs for decades. In the past, ... needed. As expected, this was a daunting and tiring process looking at endless data ... not able to navigate the complex catalog structure. , Now thanks to FireflySci, scientists are ...
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete as ... sleep, launched its Indiegogo campaign on June 23. Sound sleepers and the sleep deprived ... it effortless to use, while the integration of the Bluetooth speaker, alarm clock and ...
(Date:7/1/2015)... , ... July 01, 2015 , ... It is now ... (TBI) using single photon emission computed tomography (SPECT) according to researchers from ... which examined over 20,000 brain scans and is believed to be the largest brain ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4
... 2011 /PRNewswire-iReach/ -- WAVi Co. announced ... with SomaLogic, Inc. Under the agreement, WAVi will ... proteomic assays for an undisclosed fee. In addition, ... two clinical research studies in dementia that will ...
... 1, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... at the Canaccord Genuity Annual Growth Conference on August ... InterContinental Hotel in Boston. (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ... presentation will be accessible in the Investors section of ...
... International Isotopes Inc. (OTC Bulletin Board: INIS ... and ISO-13485 standards for the manufacture and design of ... "ISO" is the International Organization for Standardization, a ... quality standards for manufacture of a wide range of ...
Cached Biology Technology:WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc. 2International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices 2International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices 3
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/23/2015)... 23, 2015   Valencell, a leader ... of a recent study that illustrates its PerformTek ... during activity. In a study conducted at Valencell,s ... with the Apple Watch against a chest strap ... during activity. The study demonstrated that Valencell,s biometric ...
(Date:6/17/2015)... GERMANTOWN, Maryland , and HILDEN, Germany ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today launched ... DNA evidence in forensic laboratories in the United ... integrated solution to simultaneously analyze multiple key genomic markers (short ... Investigator ® Quality Sensor to evaluate the quality of ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... Mexican oregano, all contain apigenin and luteolin, flavonoids that ... inhibiting an important enzyme, according to two new University ... in two aggressive human pancreatic cancer cell lines. But ... cells with apigenin for 24 hours, then applied the ...
... BOSTON (August 15, 2013) -- In a study published ... Molecular Genetics , Drs. Donita Garland, Rosario Fernandez-Godino, and ... Massachusetts Eye and Ear, Harvard Medical School, along with ... genetically engineered to have an inherited form of macular ...
... MEDFORD/SOMERVILLE, Mass. In two recently published papers, ... techniques for predicting the severity of seasonal cholera epidemics ... of accuracy than other methods based on remote ... may provide the essential lead time to strengthen intervention ...
Cached Biology News:Celery, artichokes contain flavonoids that kill human pancreatic cancer cells 2Researchers report a critical role for the complement system in early macular degeneration 2Researchers report a critical role for the complement system in early macular degeneration 3Tufts scientists develop new early warning system for cholera epidemics 2Tufts scientists develop new early warning system for cholera epidemics 3
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Phenytoin-BSA Isolated IgY DFc Drug...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Biology Products: